Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Brentuximab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT02275598
What this trial is testing

Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma

Who this might be right for
Hodgkin Lymphoma
University of Modena and Reggio Emilia 12
Large-scale testing (Phase 3)Study completedNCT01777152
What this trial is testing

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Who this might be right for
Anaplastic Large-Cell LymphomaNon-Hodgkin LymphomaT-Cell Lymphoma
Seagen Inc. 452
Testing effectiveness (Phase 2)Study completedNCT02244021
What this trial is testing

BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV

Who this might be right for
Relapsed/Refractory Hodgkin's Lymphoma
Fondazione Italiana Linfomi - ETS 13
Not applicableUnknownNCT03440788
What this trial is testing

Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin

Who this might be right for
Relapsed or Refractory Hodgkin's Lymphoma
Multinational Center for Quality of Life Research, Russia 70
Testing effectiveness (Phase 2)Looking for participantsNCT03356054
What this trial is testing

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse

Who this might be right for
DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland 37
Not applicableEnded earlyNCT01841021
What this trial is testing

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Who this might be right for
Peripheral T-Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute 1
Early research (Phase 1)UnknownNCT02280993
What this trial is testing

Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients

Who this might be right for
Hodgkin LymphomaRefractoryRelapse
Marjolein Spiering 72
Early research (Phase 1)Study completedNCT02086604
What this trial is testing

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Lymphoma, Large B-Cell, Diffuse
Washington University School of Medicine 37
Testing effectiveness (Phase 2)Looking for participantsNCT04561206
What this trial is testing

Brentuximab Vedotin and Nivolumab for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin Lymphoma

Who this might be right for
Relapsed Classic Hodgkin Lymphoma
City of Hope Medical Center 31
Early research (Phase 1)WithdrawnNCT02780011
What this trial is testing

Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

Who this might be right for
CD30-positive LymphomaCD30-positive Solid Tumor
Eric Bernicker, MD
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06925555
What this trial is testing

Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Who this might be right for
EBV-Positive Diffuse Large B-Cell Lymphoma, NosBrentuximab Vedotin
The First Affiliated Hospital with Nanjing Medical University 25
Large-scale testing (Phase 3)Study completedNCT01578499
What this trial is testing

Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)

Who this might be right for
Primary Cutaneous Anaplastic Large Cell LymphomaMycosis FungoidesCutaneous T-Cell Lymphoma
Millennium Pharmaceuticals, Inc. 131
Testing effectiveness (Phase 2)Ended earlyNCT02462538
What this trial is testing

Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL

Who this might be right for
ALK+ Anaplastic Large Cell Lymphoma
Arbeitsgemeinschaft medikamentoese Tumortherapie 3
Testing effectiveness (Phase 2)Looking for participantsNCT05039073
What this trial is testing

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
Emory University 46
Large-scale testing (Phase 3)Ended earlyNCT03138499
What this trial is testing

Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

Who this might be right for
Hodgkin's Disease
Bristol-Myers Squibb 23
Testing effectiveness (Phase 2)Study completedNCT02292979
What this trial is testing

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.

Who this might be right for
Hodgkin Lymphoma
The Lymphoma Academic Research Organisation 170
Early research (Phase 1)Study completedNCT01309789
What this trial is testing

Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Who this might be right for
Lymphoma, Large-Cell, AnaplasticLymphoma, NK-cellLymphoma, T-cell
Seagen Inc. 39
Testing effectiveness (Phase 2)UnknownNCT06201507
What this trial is testing

BV-AVD-R Treatment Children Hodgkin's Lymphoma

Who this might be right for
Hodgkin Lymphoma
Beijing Children's Hospital 44
Testing effectiveness (Phase 2)UnknownNCT03474133
What this trial is testing

Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)

Who this might be right for
Hodgkin's Lymphoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 80
Testing effectiveness (Phase 2)Study completedNCT02243436
What this trial is testing

Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma

Who this might be right for
CLASSICAL HODGKIN LYMPHOMA
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 67
Next Page